Topics

FDA calls generic Zantac carcinogen levels 'unacceptable,' but pushes back against lab claims

06:58 EDT 3 Oct 2019 | BioPharmaDive

Regulators say the third-party lab isn't using a suitable method in tests showing even higher levels of NDMA, a probable human carcinogen.

Original Article: FDA calls generic Zantac carcinogen levels 'unacceptable,' but pushes back against lab claims

NEXT ARTICLE

More From BioPortfolio on "FDA calls generic Zantac carcinogen levels 'unacceptable,' but pushes back against lab claims"

Quick Search